Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Option for Advanced HER2+ Solid Tumors

Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.

Related Keywords

Baylor University ,Texas ,United States ,Dallas ,American ,Ww Caruth Jr ,Ronanj Kelly ,Trastuzumab Deruxtecan ,Baylor Scott White Health ,Immunology At Baylor University Medical Center ,College Of American Pathologists ,Baylor Scott ,White Health ,North Texas ,White Charles ,Cancer Center ,Baylor University Medical Center ,Endowed Chair ,American Pathologists ,Patients With ,Expressing Solid Tumors ,Primary Results From ,D ,Nba ,Fda Approval Of Trastuzumab Deruxtecan ,Pretreated ,Dvanced Her2 Positive Solid Tumors ,